Beyond thyroid cancer, siRNA-mediated downregulation of oncogenic lncRNAs such as DLGAP1-AS2 has been shown to improve carboplatin chemosensitivity in lung cancer cells, reinforcing the translational promise of ncRNA modulation as a therapeutic paradigm [109]. This evidence concerns the gene DLGAP1 and thyroid cancer.